Lilly Acquires Preclinical Non-Viral DNA Delivery Platform for $202M

May 20, 2026, Eli Lilly acquired Engage Biologics, a preclinical biotechnology company developing a non-viral DNA delivery platform, in a transaction valued at up to $202 million, including upfront and milestone-based payments.¹ The deal places Engage’s Tethosome platform inside Lilly’s broader genetic medicines organization.

“With a lean organization and modest seed funding, I am incredibly proud of the rapid progress Engage has made toward a new class of genetic medicines. This is a testament to what a nimble, passionate team can achieve with the tools of synthetic biology,” said Will Olsen, CEO, Engage, in a press release.¹ “We are excited to begin our next chapter with Lilly, which has demonstrated unmatched speed and a uniquely forward-thinking approach to genetic medicine. We believe that the combination of Engage’s platform with Lilly’s significant capabilities will meaningfully accelerate development of new genetic therapies.”

What Did Lilly Acquire in Non-Viral Genetic Medicines?

Engage has focused on non-viral DNA delivery systems intended to address two technical barriers cited in the announcement: nuclear localization and innate immune sensing.¹ The company’s Tethosome platform is described as combining engineered DNA payloads with lipid nanoparticle delivery and an messenger RNA (mRNA)-encoded proprietary technology intended to improve localization and expression.

Non-viral gene delivery has long been investigated as an alternative to viral vectors, with potential advantages related to design flexibility and manufacturing scalability, but delivery efficiency, tissue targeting, and immune activation remain central technical constraints.²

How Could Non-Viral DNA Delivery Affect Genetic Medicines?

The transaction reflects continued interest in platforms that may allow genetic medicines to be engineered, manufactured, and modified using modular components.¹ Engage’s approach uses lipid nanoparticles, a delivery modality with an established role in nucleic acid delivery, particularly for mRNA-based products.³ However, translating lipid nanoparticle experience from mRNA to DNA payloads is not a simple substitution. DNA payloads introduce distinct requirements, including intracellular trafficking and nuclear access.¹ Engage states that its DNA payloads are engineered to improve tolerability while preserving attributes associated with DNA-based therapies, including durability and programmability.

What is Known About the Tethosome Platform?

Engage is a preclinical company, and the announcement did not identify clinical candidates, active investigational new drug applications, trial designs, or regulatory filings.¹ As a result, the immediate development implications are primarily strategic and technical. Lilly gains access to a delivery system intended to improve potency, tolerability, and redosability in non-viral DNA medicines, while Engage’s programs move into a larger genetic medicines infrastructure.

From a regulatory perspective, genetic medicine programs typically require detailed characterization of product design, delivery system performance, biodistribution, immune response, and long-term follow-up considerations, particularly when durable expression is anticipated.⁴ These expectations are likely to shape any future clinical translation of a DNA-based platform, regardless of whether the delivery system is viral or non-viral.

References

1. Engage Bio acquired by Lilly to accelerate development of non-viral genetic medicines. Business Wire. News release. May 20, 2026. Accessed May 20, 2026. https://www.businesswire.com/news/home/20260520932076/en/Engage-Bio-Acquired-by-Lilly-to-Accelerate-Development-of-Non-Viral-Genetic-Medicines
2. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. Nat Rev Genet. 2014;15(8):541-555. doi:10.1038/nrg3763
3. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078-1094. doi:10.1038/s41578-021-00358-0
4. US Food and Drug Administration. Long Term Follow-Up After Administration of Human Gene Therapy Products: Guidance for Industry. January 2020.